Skip to content
DataLookout
Menu

PNOC041NCT07226453

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 10 → 13 locations
  2. Minor Study sites revised (12)
  3. Minor Study sites: 10 to 12
  4. Notable Eligibility criteria revised
    • Study description revised
    • Site details revised at 3 of 10 sites
  5. Minor Study sites revised (10)v13
  6. Minor Site details revised at 1 of 10 sitesv12
  7. Minor Trial sites expanded: 5 → 10 locationsv11
  8. Minor Site details revised at 1 of 5 sitesv10
  9. Minor Study sites: 3 to 5v9
  10. Minor Study sites: 1 to 3v8
  11. Notable Eligibility criteria expanded, about 32 wordsv7
  12. Notable Recruitment opened
    • Start date changed from estimate of Jun 1, 2026 to May 5, 2026
    • Site details revised
    v6
  13. Minor Start date: May 4, 2026 to Jun 1, 2026v5
  14. Notable Start date: Mar 4, 2026 to May 4, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Site details revised
    v4
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 28, 2026 to Mar 4, 2026
    • Site details revised
    v2
  16. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants with changes in biomarkers between the pre-and post-metformin treated samples (Target Validation Phase)
Timeframe: From initiation of study treatment until surgical resection of tumor, approximated 6 weeks
Disease Stabilization Rate (Efficacy Phase)
Timeframe: From initiation of study treatment until discontinuation of treatment, up to 2 years

Arms and interventions

Target Validation (TV) Phase (Metformin)Experimental

Participants will each receive daily oral metformin with a weekly schedule starting at 250 mg/m\^2 twice a day (BID) for the first week, then increasing to 500 mg/m\^2 BID for week 2, 1000 mg/m\^2 BID for week 3, and then 1666 mg/m\^2 BID for week 4-6 prior to planned surgery. Participants with no measurable disease following surgical intervention may either go off treatment or continue metformin at the physician's discretion. Participants have the option of continuing on the efficacy phase of the study without undergoing planned surgery no demonstrated progressive disease on pre-surgery MRI AND if the family opts to continue treatment with metformin without undergoing surgical resection of the tumor. Participants with measurable tumor by RAPNO criteria following surgery may continue onto efficacy phase and receive maintenance metformin until disease progression or till there are unacceptable adverse event(s).

Efficacy Phase (Metformin)Experimental

Participants with recurrent or progressive PFA ependymoma that have failed upfront surgery and radiation will receive daily oral metformin until disease progression or till there are unacceptable adverse event(s). Disease response will be assessed by MRI imaging using RAPNO criteria. Participants already enrolled on the TV phase may enroll in this phase if they have measurable disease post-surgery. Treatment may continue until disease progression or until there are unacceptable adverse event(s).

Drugs: Metformin

Procedures: Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS)

Sites

13 sites in 2 countries

United States 12, Brazil 1